STERO aims to solve an unmet need by using Cannabidiol (CBD), a non-psychotropic component of Cannabis sativa, which has been shown to possess potent immunomodulatory and anti-inflammatory properties in various indications.

Our preliminary results in a phase II trial in GVHD show that CBD administration enhanced the therapeutic effect of steroids or reduced the steroid dosage while maintaining or improving the steroid’s original therapeutic effect.

In all patients treated, the steroid dose administered with CBD was gradually decreased over time. patients refractory to steroid treatment also presented significant improvement to the CBD treatment.

The company plans to validate its concept in various autoimmune diseases.
The company’s product ST-101 is targeted for steroid sparing in multiple indications.

The company’s main clinical trial is in inflammatory bowel diseases (IBD), steroid dependent Crohn’s disease.
The phase IIa clinical trial started on Q4 2019.

In addition, The company has commenced an another clinical trtial in Chronic Urticaria (Hives).
The phase IIa clinical trial started on Q1 2020.

with more indications in the pipeline for 2020-2021.